Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-FVP-t (Favipiravir) vs SOC in Mild to Moderate COVID-19
NCT04501783Phase 3Completed
- Sponsor
- R-Pharm
- Start
- May 2020
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by R-Pharm. Primary endpoints: Time to clinical improvement at Day 28 and Time to viral clearance at Day 28. Started May 2020; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04501783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501783.